Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis

2020 ◽  
Author(s):  
Ranjan Gupta ◽  
Akhilesh Yadav ◽  
Amita Aggarwal
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Soluble Cd163

scholarly journals Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis

2007 ◽  
Vol 56 (6) ◽  
pp. 1894-1903 ◽  
Author(s):  
Milena Pitashny ◽  
Noa Schwartz ◽  
Xiaoping Qing ◽  
Bernard Hojaili ◽  
Cynthia Aranow ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Lipocalin 2

SAT0413 Urinary Lipocalin-2 as a Biomarker of Renal Disease Activity in Patients with Lupus Nephritis: A Prospective Study

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 808.3-809
Author(s):  
N. M. Gamal ◽  
N.M. Mustafa ◽  
E. A.M. Abda ◽  
O. Afifi ◽  
N. Fathi
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Prospective Study ◽  
Disease Activity ◽  
Lipocalin 2 ◽  
A Prospective Study

scholarly journals Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment

RMD Open ◽  
2020 ◽  
Vol 6 (2) ◽  
pp. e001257
Author(s):  
Jennifer C Davies ◽  
Angela Midgley ◽  
Emil Carlsson ◽  
Sean Donohue ◽  
Ian N Bruce ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Calcium Binding ◽  
Therapeutic Potential ◽  
Activity Index ◽  
S100 Proteins ◽  
Response To Treatment ◽  
Inflammatory Disorder ◽  
Serum And Urine

BackgroundApproximately 30% of patients with the systemic autoimmune/inflammatory disorder systemic lupus erythematosus (SLE) develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease. The Maximizing SLE Therapeutic Potential by Application of Novel and Systemic Approaches and the Engineering Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of calcium-binding S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab (RTX) in LN.MethodsS100A8/A9 and S100A12 proteins were quantified in the serum and urine of 243 patients with SLE from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) study and 48 controls matched for age using Meso Scale Discovery’s technology to determine whether they perform as biomarkers for active LN and/or may be used to predict response to treatment with RTX. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment.ResultsSerum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) levels are elevated in patients with SLE. While serum and urine S100 levels do not correlate with global disease activity (SLE Disease Activity Index), levels in urine and urine/serum ratios are elevated in patients with active LN. S100 proteins perform better as biomarkers for active LN involvement in patients with SLE who tested positive for anti-double-stranded DNA antibodies. Binary logistic regression and area under the curve analyses suggest the combination of serum S100A8/A9 and S100A12 can predict response to RTX treatment in LN after 6 months.ConclusionsFindings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with RTX.

Urinary Angiotensinogen Predicts Renal Disease Activity in Lupus Nephritis

2019 ◽  
Vol 31 (17) ◽  
pp. 1289-1301
Author(s):  
Meng Shi ◽  
Weihong Luo ◽  
Xiaodan Feng ◽  
Lingwei Jin ◽  
Manqiu Yang ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Urinary Angiotensinogen

scholarly journals Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis

2009 ◽  
Vol 11 (6) ◽  
pp. R188 ◽  
Author(s):  
Christopher Sjöwall ◽  
Agneta Zickert ◽  
Thomas Skogh ◽  
Jonas Wetterö ◽  
Iva Gunnarsson
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Serum Levels ◽  
Response To Therapy ◽  
C Reactive Protein ◽  
Reactive Protein

Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis

2009 ◽  
Vol 36 (10) ◽  
pp. 2224-2230 ◽  
Author(s):  
ADNAN N. KIANI ◽  
KRISTEN JOHNSON ◽  
CATHERINE CHEN ◽  
EDWARD DIEHL ◽  
HUAIZHONG HU ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Creatinine Ratio ◽  
Longitudinal Assessment ◽  
Urine Protein ◽  
Monocyte Chemoattractant Protein 1 ◽  
Monocyte Chemoattractant ◽  
Monocyte Chemoattractant Protein

Objective.Renal biopsy is the “gold standard” to determine renal activity in systemic lupus erythematosus (SLE), but it is expensive, invasive, and carries risk. Osteoprotegerin (OPG) is produced by the heart, lungs, kidney, and bone. Monocyte chemoattractant protein-1 (MCP-1), a chemotactic cytokine, is involved in the progression of glomerular and tubulointerstitial injury. We investigated both urine OPG and MCP-1 as potential biomarkers for lupus nephritis.Methods.Our subjects, 87 patients with SLE (88% women; 48% African American, 41% Caucasian, 11% other), mean age 44 years, were followed monthly to quarterly. Urinary OPG (pg/ml) and MCP-1 (pg/ml) were measured (Luminex MAP bead assay).Results.OPG concentrations were strongly associated with global disease activity and with both renal activity on a visual analog scale (VAS) (p = 0.0006) and renal disease activity descriptors of the SELENA SLEDAI, including hematuria (p = 0.001) and a positive anti-dsDNA (p = 0.013). MCP-1 was also associated with the renal VAS (p = 0.032), renal disease activity descriptors of SELENA SLEDAI, including hematuria (p = 0.027), and with a positive anti-dsDNA (p = 0.016). We also examined the relationship between the biomarkers and having a urine protein to creatinine ratio (pr/cr) ≥ 0.5. Among patients with medium or high OPG, 46% had urine pr/cr ≥ 0.5, compared to only 23% among those with low OPG (p = 0.032). The 2 biomarkers were strongly correlated with each other (Spearman correlation coefficient 0.77, p < 0.0001).Conclusion.The lack of availability of urine biomarkers has hampered development of new therapies for lupus nephritis. Urine MCP-1 and OPG were both associated with measures of lupus renal disease activity. Medium or high levels of OPG were predictive of a urine protein/creatinine ratio of ≥ 0.5. Further study, including longitudinal assessment and correlation with concurrent renal biopsies, is necessary before this assay can be used in the routine clinic setting.

scholarly journals THU0250 URINE AND SERUM S100 PROTEINS ASSOCIATE WITH LUPUS NEPHRITIS AND RESPONSE TO TREATMENT

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 352.1-352
Author(s):  
J. Davies ◽  
A. Midgley ◽  
S. Donohue ◽  
I. N. Bruce ◽  
M. Beresford ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Nephritis ◽  
Renal Disease ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
S100 Proteins ◽  
Response To Treatment ◽  
Systemic Lupus ◽  
Systemic Jia ◽  
Serum And Urine

Background:Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Approximately 30% of SLE patients develop lupus nephritis (LN) that affects treatment and prognosis. Easily accessible biomarkers do not exist to reliably predict renal disease1. Recently, calcium-binding S100 proteins have been suggested as biomarkers in systemic inflammatory conditions, including SLE2,3.Objectives:The MASTERPLANS Consortium aims to identify indicators of treatment responses in SLE. This study tested the applicability of S100 proteins in serum and urine as biomarkers for disease activity and response to treatment with rituximab in LN.Methods:S100A8/A9 and S100A12 proteins were quantified in the serum and urine of 243 SLE patients from the BILAG-BR study and 48 matched controls using MSD technology to determine whether they perform as biomarkers for active LN (n=85 SLE patients) and/or may be used to predict response to treatment with rituximab. Renal disease activity and response to treatment was based on BILAG-BR scores and changes in response to treatment4,5.Results:Serum S100A12 (p<0.001), and serum and urine S100A8/A9 (p<0.001) are elevated in SLE patients. While serum and urine S100 levels do not correlate with global SLE disease activity (SLEDAI), levels in urine and urine/serum ratios are elevated in SLE patients with active LN (S100A8/A9: urine p>0.005, urine/serum p<0.05; S100A12: urine p<0.05, serum/urine p<0.005). S100 proteins perform better as biomarkers for active LN involvement in SLE patients positive for anti-dsDNA antibodies. Lastly, binary logistic regression and AUC analysis suggests the combination of serum S100A8/A9 and S100A12 to predict response to RTX treatment in LN after 6 months.Conclusion:Findings from this study show promise for clinical application of S100 proteins to predict active renal disease in SLE and response to treatment with rituximab. Significantly overlapping values between groups currently prohibit the definition of cut-off values and prospective studies are required to validate findings.References:[1]Reppe Moe SE,et al. Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort.Lupus. 2019;28(7):818-825.[2]Austermann J,et al. S100 proteins in rheumatic diseases.Nat Rev Rheumatol. 2018;14(9):528-541.[3]Tydén H,et al. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus.Lupus. 2017;26(2):139-149.[4]Yee CS,et al. Numerical scoring for the BILAG-2004 index.Rheumatology.2010; 49(9):1665-1669.[5]McCarthyet al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the british isles lupus assessment group biologics register.Rheumatol. 2018;57(3):470-479.Acknowledgments:Clinical information and serum/urine samples from SLE patients were provided by BILAG-BR centres.Disclosure of Interests:Jennifer Davies: None declared, Angela Midgley: None declared, Sean Donohue: None declared, Ian N. Bruce Grant/research support from: Genzyme Sanofi, GSK, and UCB, Consultant of: Eli Lilly, AstraZeneca, UCB, Iltoo, and Merck Serono, Speakers bureau: UCB, Michael Beresford: None declared, Christian Hedrich Grant/research support from: Research grant support from Novartis (Molecular pathophysiology of psoriasis)., Speakers bureau: Speaker honoraria from Roche (pathophysiology of polyarticular JIA and systemic JIA); involved in advisory boards for Novartis (systemic JIA and IL-1 mediated diseases).

Sign in / Sign up

Export Citation Format

Share Document